GNCA vs. SCPS, VAXX, NAVB, EVLO, CMRA, GNCAQ, ARDS, STAB, CALA, and EFTR
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry.
Genocea Biosciences vs.
Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.
In the previous week, Scopus BioPharma and Scopus BioPharma both had 1 articles in the media. Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.
Scopus BioPharma has higher earnings, but lower revenue than Genocea Biosciences.
0.6% of Genocea Biosciences shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Genocea Biosciences received 386 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 56.07% of users gave Genocea Biosciences an outperform vote.
Scopus BioPharma has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
Summary
Scopus BioPharma beats Genocea Biosciences on 5 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genocea Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:GNCA) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy GNCA Stock Free GNCA Stock Alerts